Trexquant Investment LP Invests $3.10 Million in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)

Trexquant Investment LP acquired a new stake in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm acquired 143,514 shares of the company’s stock, valued at approximately $3,101,000. Trexquant Investment LP owned approximately 0.17% of Syndax Pharmaceuticals as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. CWM LLC grew its stake in Syndax Pharmaceuticals by 415.3% in the fourth quarter. CWM LLC now owns 1,685 shares of the company’s stock valued at $36,000 after acquiring an additional 1,358 shares during the period. MeadowBrook Investment Advisors LLC purchased a new position in shares of Syndax Pharmaceuticals during the fourth quarter valued at approximately $37,000. Quadrant Capital Group LLC boosted its position in shares of Syndax Pharmaceuticals by 158.3% during the fourth quarter. Quadrant Capital Group LLC now owns 2,441 shares of the company’s stock valued at $53,000 after buying an additional 1,496 shares during the last quarter. Annandale Capital LLC bought a new stake in Syndax Pharmaceuticals during the third quarter worth $67,000. Finally, Signaturefd LLC lifted its holdings in Syndax Pharmaceuticals by 2,874.6% during the fourth quarter. Signaturefd LLC now owns 3,748 shares of the company’s stock worth $81,000 after acquiring an additional 3,622 shares during the period.

Syndax Pharmaceuticals Trading Up 0.8 %

Shares of SNDX stock traded up $0.17 during trading hours on Friday, reaching $20.28. 821,743 shares of the company’s stock were exchanged, compared to its average volume of 950,271. The stock’s 50 day moving average is $21.85 and its 200-day moving average is $20.76. The company has a market cap of $1.72 billion, a price-to-earnings ratio of -6.30 and a beta of 1.01. Syndax Pharmaceuticals, Inc. has a fifty-two week low of $11.22 and a fifty-two week high of $25.34.

Syndax Pharmaceuticals (NASDAQ:SNDX) last posted its quarterly earnings results on Wednesday, May 8th. The company reported ($0.85) EPS for the quarter, beating the consensus estimate of ($0.96) by $0.11. During the same quarter in the previous year, the business earned ($0.59) earnings per share. Equities analysts anticipate that Syndax Pharmaceuticals, Inc. will post -3.58 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research firms recently issued reports on SNDX. Stifel Nicolaus boosted their price objective on Syndax Pharmaceuticals from $39.00 to $40.00 and gave the company a “buy” rating in a research note on Thursday, May 9th. Scotiabank cut Syndax Pharmaceuticals from a “sector outperform” rating to a “sector perform” rating and decreased their target price for the stock from $36.00 to $23.00 in a report on Wednesday, January 31st. JPMorgan Chase & Co. reissued an “overweight” rating and set a $34.00 price target on shares of Syndax Pharmaceuticals in a report on Tuesday. Citigroup decreased their price target on Syndax Pharmaceuticals from $32.00 to $30.00 and set a “buy” rating on the stock in a report on Thursday, May 9th. Finally, HC Wainwright restated a “buy” rating and set a $41.00 price objective on shares of Syndax Pharmaceuticals in a research report on Thursday, May 9th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and ten have assigned a buy rating to the stock. According to MarketBeat, Syndax Pharmaceuticals has an average rating of “Moderate Buy” and a consensus price target of $34.42.

Syndax Pharmaceuticals Profile

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).